The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic

被引:146
作者
Walsh, SL
Eissenberg, T
机构
[1] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Behav Pharmacol Res Unit, Baltimore, MD 21224 USA
[2] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA 23298 USA
关键词
buprenorphine; clinical pharmacology; humans; review; opioid; naloxone;
D O I
10.1016/S0376-8716(03)00056-5
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This paper will review clinical pharmacology studies on buprenorphine, a mixed opioid agonist-antagonist currently approved as a treatment for opioid dependence. The focus is on studies characterizing buprenorphine's pharmacodynamic actions, including its safety, abuse liability, withdrawal suppression and withdrawal precipitation capacity, physical dependence potential, cross-tolerance and duration of action as well as a review of the pharmacological profile of buprenorphine/naloxone combinations. The findings from these clinical pharmacology studies are synthesized and presented in a framework designed to (1) inform clinicians about the advantages and disadvantages of buprenorphine as an opioid maintenance agent, and (2) provide information about dosing procedures that may optimize the use of buprenorphine in the clinic. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S13 / S27
页数:15
相关论文
共 82 条
[1]   ALTERNATE-DAY DOSING DURING BUPRENORPHINE TREATMENT OF OPIOID DEPENDENCE [J].
AMASS, L ;
BICKEL, WK ;
HIGGINS, ST ;
BADGER, GJ .
LIFE SCIENCES, 1994, 54 (17) :1215-1228
[2]   Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans [J].
Amass, L ;
Bickel, WK ;
Crean, JP ;
Blake, J ;
Higgins, ST .
PSYCHOPHARMACOLOGY, 1998, 136 (03) :217-225
[3]   INTRINSIC ACTIVITY - PARTIAL AGONISTS AND PARTIAL ANTAGONISTS [J].
ARIENS, EJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1983, 5 :S8-S15
[4]  
Bedi N. S., 1998, Indian Journal of Physiology and Pharmacology, V42, P95
[5]  
BERKOWITZ BA, 1975, J PHARMACOL EXP THER, V195, P499
[6]  
BICKEL WK, 1988, J PHARMACOL EXP THER, V247, P47
[7]   Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients [J].
Bickel, WK ;
Amass, L ;
Crean, JP ;
Badger, GJ .
PSYCHOPHARMACOLOGY, 1999, 146 (02) :111-118
[8]   EFFECTS OF BUPRENORPHINE IN HEROIN-ADDICTS [J].
BLOM, Y ;
BONDESSON, U ;
GUNNE, LM .
DRUG AND ALCOHOL DEPENDENCE, 1987, 20 (01) :1-7
[9]   A CONTROLLED COMPARISON OF BUPRENORPHINE AND CLONIDINE FOR ACUTE DETOXIFICATION FROM OPIOIDS [J].
CHESKIN, LJ ;
FUDALA, PJ ;
JOHNSON, RE .
DRUG AND ALCOHOL DEPENDENCE, 1994, 36 (02) :115-121
[10]  
Clark NC, 2002, MED J AUSTRALIA, V176, P166